Core Viewpoint - The article discusses the advancements and potential of Gestala Technology, a company focused on ultrasound brain-machine interface technology, which aims to provide non-invasive solutions for chronic pain management and other neurological conditions [6][9]. Company Overview - Gestala Technology recently secured 150 million yuan in angel funding, led by Guosheng Capital and Daotong Investment, to support the development of its first product and preliminary clinical trials [6]. - The company was founded in January 2023 by Peng Lei and Chen Tianqiao, with a team of approximately 15 experts from various fields including acoustics, neuroscience, and AI [6][10]. Technology Insights - The main focus of Gestala's technology is on non-invasive ultrasound brain imaging and neural modulation, which has gained attention due to its potential to create a "read-write" system for the brain [7][8]. - Ultrasound technology has unique advantages over other brain modulation methods, allowing for targeted stimulation of specific brain regions without damaging neurons [8]. - The mechanism involves converting mechanical waves into bioelectrical signals that can stimulate neurons, with the ability to target areas deep within the brain [8][9]. Clinical Applications - The initial clinical application for Gestala is chronic pain management, which has a large patient base and objective efficacy evaluation [9]. - Previous studies indicate that a single 45-minute ultrasound stimulation can reduce pain scores by 50%, with effects lasting 1-2 weeks [9]. - The company is also exploring applications for mental health conditions such as depression and PTSD, as well as neurodegenerative diseases like Alzheimer's [9]. Future Development Plans - Gestala's development strategy includes a phased approach: starting with non-invasive neural modulation, progressing to stable brain activity reading, and eventually integrating gene editing and protein engineering technologies [10]. - The company believes that China has unique advantages in clinical resources, trial costs, and manufacturing supply chains, which can facilitate its growth in the ultrasound brain-machine interface sector [10].

Core Viewpoint - Gestala Technology is developing a non-invasive ultrasound brain-machine interface aimed at chronic pain management, with plans to initiate NMPA registration for Class III medical devices by the end of 2026 [2]. Group 1: Company Overview - Gestala Technology recently secured 150 million yuan in angel round financing, led by Guosheng Capital and Daotong Investment, with participation from several other institutions [3]. - The company was founded in January 2023 by Peng Lei and Chen Tianqiao, with a team of approximately 15 experts in various fields including acoustics, neuroscience, and AI [3]. Group 2: Technology and Mechanism - Current brain-machine interface solutions are categorized into invasive and non-invasive types, with ultrasound technology emerging as a promising non-invasive option that can target deep brain areas [4]. - Ultrasound technology has unique advantages, including the ability to modulate specific brain regions without damaging neurons, thanks to recent breakthroughs in low-intensity focused ultrasound [4][5]. - The core of ultrasound neuromodulation involves converting mechanical waves into bioelectrical signals that neurons can respond to, utilizing various physical effects such as thermal and cavitation effects [5][6]. Group 3: Clinical Applications and Challenges - Gestala Technology aims to address chronic pain management as its first clinical application, supported by existing data showing a 50% reduction in pain scores after a single 45-minute ultrasound session [7]. - The company is also exploring applications for mental health disorders and neurodegenerative diseases, collaborating with top hospitals for clinical research [7]. - Challenges include ensuring precise control of ultrasound parameters and overcoming limitations in time resolution for real-time applications [6][7]. Group 4: Future Development and Market Position - The company plans a phased approach to development, starting with non-invasive neuromodulation, followed by enhanced brain activity reading capabilities, and eventually integrating genetic editing technologies [8]. - Gestala Technology believes that China has unique advantages in the ultrasound brain-machine interface sector, including rich clinical resources and supportive national policies [8].

Core Viewpoint - The article discusses a breakthrough in medical technology that allows for the safe opening and closing of the blood-brain barrier (BBB) using an ultrasound device called UltraBrainPad, which enhances drug delivery for treating glioblastoma patients [1][2]. Group 1: Technology and Methodology - The UltraBrainPad device enables real-time observation of the brain using a handheld ultrasound probe, allowing doctors to select treatment targets and open the BBB with high precision [2]. - The research team optimized the ultrasound parameters to open the BBB in just 3 minutes, resulting in an average increase of 8 times in drug concentration compared to untreated brain tissue [1][2]. - The technology is described as a "ultrasound brain-machine interface," which not only facilitates drug delivery but also allows for the monitoring and adjustment of brain functions [2][3]. Group 2: Clinical Applications and Future Research - Glioblastoma accounts for approximately 30% of brain tumors, with an average survival time of around 16 months for patients [2]. - Future clinical trials will explore the application of this technology in treating other neurological diseases, including Alzheimer's and Parkinson's disease, as well as various functional neurological disorders [3]. - The research team plans to initiate the "ROAR-BBBO" clinical study to treat recurrent glioblastoma patients, aiming to expand the use of ultrasound brain-machine interface technology beyond drug treatment to include neural regulation and brain-machine integration [3].